Literature DB >> 23205489

Advances in predicting acute GVHD.

Andrew C Harris1, James L M Ferrara, John E Levine.   

Abstract

Acute graft-versus-host disease (GVHD) is a leading cause of non-relapse mortality following allogeneic haematopoietic cell transplantation. Attempts to improve treatment response in clinically-established GVHD have not improved overall survival, often due to the increased risk of infectious complications. Alternative approaches to decrease GVHD-related morbidity and mortality have focused on the ability to predict GVHD prior to clinical manifestation in an effort to provide an opportunity to abort GVHD development, and to gain new insights into GVHD pathophysiology. This review outlines the research efforts to date that have identified clinical and laboratory-based factors that are predictive of acute GVHD and describes future directions in developing algorithms that will improve the ability to predict the development of clinically relevant GVHD.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23205489      PMCID: PMC3552019          DOI: 10.1111/bjh.12142

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  100 in total

Review 1.  Back to the future: mismatched unrelated donor, haploidentical related donor, or unrelated umbilical cord blood transplantation?

Authors:  Claudio Anasetti; Franco Aversa; Claudio G Brunstein
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

2.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation.

Authors:  Madan Jagasia; Mukta Arora; Mary E D Flowers; Nelson J Chao; Philip L McCarthy; Corey S Cutler; Alvaro Urbano-Ispizua; Steven Z Pavletic; Michael D Haagenson; Mei-Jie Zhang; Joseph H Antin; Brian J Bolwell; Christopher Bredeson; Jean-Yves Cahn; Mitchell Cairo; Robert Peter Gale; Vikas Gupta; Stephanie J Lee; Mark Litzow; Daniel J Weisdorf; Mary M Horowitz; Theresa Hahn
Journal:  Blood       Date:  2011-10-18       Impact factor: 22.113

3.  Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study.

Authors:  John E Levine; Brent R Logan; Juan Wu; Amin M Alousi; Javier Bolaños-Meade; James L M Ferrara; Vincent T Ho; Daniel J Weisdorf; Sophie Paczesny
Journal:  Blood       Date:  2012-03-01       Impact factor: 22.113

4.  Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis.

Authors:  Mary Eapen; John P Klein; Guillermo F Sanz; Stephen Spellman; Annalisa Ruggeri; Claudio Anasetti; Maria Brown; Richard E Champlin; Joan Garcia-Lopez; Gareth Hattersely; Gesine Koegler; Mary J Laughlin; Gerard Michel; Samir K Nabhan; Franklin O Smith; Mary M Horowitz; Eliane Gluckman; Vanderson Rocha
Journal:  Lancet Oncol       Date:  2011-10-06       Impact factor: 41.316

Review 5.  Clinical perspectives for regulatory T cells in transplantation tolerance.

Authors:  Keli L Hippen; James L Riley; Carl H June; Bruce R Blazar
Journal:  Semin Immunol       Date:  2011-08-05       Impact factor: 11.130

6.  Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD.

Authors:  S Thiant; M Labalette; J Trauet; V Coiteux; E de Berranger; J-P Dessaint; I Yakoub-Agha
Journal:  Bone Marrow Transplant       Date:  2010-12-06       Impact factor: 5.483

Review 7.  Homeostatic maintenance of T cells and natural killer cells.

Authors:  Onur Boyman; Carsten Krieg; Dirk Homann; Jonathan Sprent
Journal:  Cell Mol Life Sci       Date:  2012-03-30       Impact factor: 9.261

Review 8.  The WAP protein Trappin-2/Elafin: a handyman in the regulation of inflammatory and immune responses.

Authors:  Thomas Verrier; Brigitte Solhonne; Jean-Michel Sallenave; Ignacio Garcia-Verdugo
Journal:  Int J Biochem Cell Biol       Date:  2012-05-23       Impact factor: 5.085

9.  A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.

Authors:  Mark B Geyer; Judith S Jacobson; Jason Freedman; Diane George; Virginia Moore; Carmella van de Ven; Prakash Satwani; Monica Bhatia; James H Garvin; Mary Brigid Bradley; Lauren Harrison; Erin Morris; Phyllis Della-Latta; Joseph Schwartz; Lee A Baxter-Lowe; Mitchell S Cairo
Journal:  Br J Haematol       Date:  2011-08-16       Impact factor: 6.998

10.  Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.

Authors:  James L M Ferrara; Andrew C Harris; Joel K Greenson; Thomas M Braun; Ernst Holler; Takanori Teshima; John E Levine; Sung W J Choi; Elisabeth Huber; Karin Landfried; Koichi Akashi; Mark Vander Lugt; Pavan Reddy; Alice Chin; Qing Zhang; Samir Hanash; Sophie Paczesny
Journal:  Blood       Date:  2011-10-06       Impact factor: 22.113

View more
  40 in total

1.  Human chorionic gonadotropin and indolamine 2,3-dioxygenase in patients with GVHD.

Authors:  A H Elmaagacli; M Ditschkowski; N K Steckel; T Gromke; H Ottinger; U Hillen; H A Baba; R Trenschel; D W Beelen; M Koldehoff
Journal:  Bone Marrow Transplant       Date:  2014-03-31       Impact factor: 5.483

2.  Allogeneic hematopoietic stem cell transplantation for patients with acute leukemia.

Authors:  Yan Chen; Yajing Xu; Gan Fu; Yi Liu; Jie Peng; Bin Fu; Xiaoyu Yuan; Hongya Xin; Yan Zhu; Qun He; Dengshu Wu; Yigang Shu; Xiaolin Li; Xielan Zhao; Fangping Chen
Journal:  Chin J Cancer Res       Date:  2013-08       Impact factor: 5.087

3.  An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

Authors:  Matthew J Hartwell; Umut Özbek; Ernst Holler; Anne S Renteria; Hannah Major-Monfried; Pavan Reddy; Mina Aziz; William J Hogan; Francis Ayuk; Yvonne A Efebera; Elizabeth O Hexner; Udomsak Bunworasate; Muna Qayed; Rainer Ordemann; Matthias Wölfl; Stephan Mielke; Attaphol Pawarode; Yi-Bin Chen; Steven Devine; Andrew C Harris; Madan Jagasia; Carrie L Kitko; Mark R Litzow; Nicolaus Kröger; Franco Locatelli; George Morales; Ryotaro Nakamura; Ran Reshef; Wolf Rösler; Daniela Weber; Kitsada Wudhikarn; Gregory A Yanik; John E Levine; James Lm Ferrara
Journal:  JCI Insight       Date:  2017-02-09

4.  Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.

Authors:  Gheath Alatrash; Kelly M Kidwell; Peter F Thall; Antonio Di Stasi; Julianne Chen; Madhushree Zope; Alyssa K Crain; Richard E Champlin; Uday Popat; Elizabeth J Shpall; Roy B Jones; Borje S Andersson
Journal:  Bone Marrow Transplant       Date:  2018-12-10       Impact factor: 5.483

5.  The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Marie Thérèse Rubio; Myriam Labopin; Didier Blaise; Gerard Socié; Rafael Rojas Contreras; Patrice Chevallier; Miguel A Sanz; Stéphane Vigouroux; Anne Huynh; Avichai Shimoni; Claude-Eric Bulabois; Nerea Caminos; Lucía López-Corral; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2015-03-13       Impact factor: 9.941

6.  Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine.

Authors:  Andrew C Harris; Jaap J Boelens; Kwang Woo Ahn; Mingwei Fei; Allistair Abraham; Andrew Artz; Christopher Dvorak; Haydar Frangoul; Cesar Freytes; Robert Peter Gale; Sanghee Hong; Hillard M Lazarus; Alison Loren; Shin Mineishi; Taiga Nishihori; Tracey O'Brien; Kirsten Williams; Marcelo C Pasquini; John E Levine
Journal:  Blood Adv       Date:  2018-06-12

7.  Breath analysis in gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Authors:  Betty K Hamilton; Lisa A Rybicki; David Grove; Christina Ferraro; Jamie Starn; Brittany Hodgeman; Jamie Elberson; Victoria Winslow; Donna Corrigan; Aaron T Gerds; Rabi Hanna; Matt E Kalaycio; Ronald M Sobecks; Navneet S Majhail; Raed A Dweik
Journal:  Blood Adv       Date:  2019-09-24

8.  Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease.

Authors:  Bin Xiao; Yu Wang; Wei Li; Megan Baker; Jian Guo; Kelly Corbet; Ephraim L Tsalik; Qi-Jing Li; Scott M Palmer; Christopher W Woods; Zhiguo Li; Nelson J Chao; You-Wen He
Journal:  Blood       Date:  2013-09-16       Impact factor: 22.113

9.  Extracellular vesicles as potential biomarkers of acute graft-vs-host disease.

Authors:  G Lia; L Brunello; S Bruno; A Carpanetto; P Omedè; M Festuccia; L Tosti; E Maffini; L Giaccone; M Arpinati; G Ciccone; M Boccadoro; A Evangelista; G Camussi; B Bruno
Journal:  Leukemia       Date:  2017-08-30       Impact factor: 11.528

10.  Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy.

Authors:  Hideki Nakasone; Mats Remberger; Lu Tian; Petter Brodin; Bita Sahaf; Fang Wu; Jonas Mattsson; Robert Lowsky; Robert Negrin; David B Miklos; Everett Meyer
Journal:  Haematologica       Date:  2015-08-06       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.